登录新浪财经APP 搜索【信披】查看更多考评等级 公告送出日期：2026年2月6日 1.公告基本信息 ■ 2.基金募集情况 ■ 注：（1）本基金募集期间的信息披露费、会计师费、律师费以及其他费用，不从基金财产中列支。 国泰基金管理有限公司 二零二六年二月六日 国泰基金管理有限公司关于旗下 （2）本基金管理人高级管理人员、基金投资和研究部门负责人认购本基金份额总量的数量区间为0份； 本基金的基金经理认购本基金份额总量的数量区间为0份。 3.其他需要提示的事项 自基金合同生效之日起，本基金管理人正式开始管理本基金。 基金份额持有人可以到销售机构的网点查询交易确认情况，也可以通过本基金管理人的网站 （www.gtfund.com）或客户服务电话（400-888-8688）查询交易确认情况。 基金管理人可根据实际情况依法决定本基金开始办理申购的具体日期，基金管理人自基金合同生效之日 起不超过3个月开始办理赎回。在确定申购开始与赎回开始时间后，基金管理人应在申购、赎回开放日 前依照《信息披露办法》的有关规定在规定媒介上公告申购与赎回的开始时间。 风险提示：本基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但 ...

（记者 王晓波） 每经头条（nbdtoutiao）——仅老年独居者就数千万，谁能帮他们从容老去？意定监护在国内诞生已14 年，距全面落地还差"最后一公里" 每经AI快讯，潍柴重机发布公告称，2026年2月3日至2月5日期间，潍柴重机接受西南证券等投资者调 研，公司柳国超参与接待，并回答了投资者提出的问题。 ...

Group 1 - The core point of the article highlights a collective decline in the three major indices, while the banking sector shows strength, and the securities and fintech sectors experience an afternoon rally [1] - As of 1:55 PM, the securities ETF Huaxia (515010) rose by 0.81%, with its holdings such as Hualin Securities hitting the daily limit, and other stocks like Huaxin Co., Guosheng Securities, and Southwest Securities also performing well [1] - The financial technology ETF Huaxia (516100) saw a slight decline of 0.22% [1] Group 2 - The Shanghai Stock Exchange reported that in January, the number of new A-share accounts reached 4.9158 million, representing a month-on-month increase of 89% and a year-on-year increase of 213%, marking the highest level in nearly 15 months since November 2024 [1] - This surge in new A-share accounts indicates a sustained boom in brokerage business, driven by the upward trend in A-shares over the past year, which has significantly boosted brokerage and proprietary trading business, leading to an overall performance recovery [1] - The management fee rate for the securities ETF Huaxia (515010) and the fintech ETF Huaxia (516100) is 0.15%, with a custody fee rate of 0.05%, which are the lowest among comparable funds, facilitating investors' access to sector trends [1]

此次修订拟将全国社保基金、基本养老保险基金、企业(职业)年金、商业保险资金、公募基金、银 行理财等机构投资者纳入战略投资者范畴，并将其界定为"资本投资者"。同时，新规明确了5%的最低 持股比例要求、资本投资者基本条件与信息披露要求。此次修订是对资本市场新"国九条"中引导中长期 资金入市的深化与落实。 近期，为进一步完善上市公司再融资战略投资者制度，中国证监会对《〈上市公司证券发行注册管 理办法〉第九条、第十条、第十一条、第十三条、第四十条、第五十七条、第六十条有关规定的适用意 见——证券期货法律适用意见第18号》（以下简称《法律适用意见》）作出修改，并向社会公开征求意 见。 《法律适用意见》拟完善战略投资者持股要求，坚持战略投资者应当持有上市公司较大比例股份， 进一步明确战略投资者认购上市公司股份原则上不低于5%，可以根据持股比例参与上市公司治理。 在完善信息披露要求方面，《法律适用意见》要求上市公司在年报中披露战略资源导入及整合的落 实情况和效果。同时，进一步强化监管要求，强调战略投资者不得通过任何方式规避最低持股比例、股 份锁定期等要求，避免代持股份、绕道减持等违规行为，防止损害制度公信力。 拟扩大战略投 ...

Group 1 - A-shares brokerage stocks have shown strong performance, with Huayin Securities rising over 7% and Dongwu Securities increasing over 3% [1] - Other notable gainers include Huaxin Securities, Guotai Haitong, and Southwest Securities, each rising over 2% [1] Group 2 - Huayin Securities has a market capitalization of 51.7 billion and a year-to-date increase of 24.85% [2] - Dongwu Securities has a market capitalization of 47.3 billion and a year-to-date increase of 4.97% [2] - Huaxin Securities has a market capitalization of 18.1 billion and a year-to-date increase of 12.01% [2] - Guotai Haitong has a market capitalization of 352.4 billion but a year-to-date decrease of 2.73% [2] - Southwest Securities has a market capitalization of 30.4 billion and a year-to-date increase of 2.23% [2]

Group 1 - The core viewpoint of the article is that Southwest Securities has received approval from the China Securities Regulatory Commission to publicly issue company bonds not exceeding 14 billion yuan, which reflects regulatory recognition of the company's comprehensive strength and risk management capabilities [1][4]. - The bond approval is valid for 24 months and can be issued in tranches, providing strong momentum for the company to deepen its core advantages and empower the real economy [1][4]. - As a leading brokerage rooted in Southwest China, the company continues to demonstrate its core competitiveness by focusing on regional markets and achieving significant results in areas such as technology finance and green finance [4]. Group 2 - For the first three quarters of 2025, the company's proprietary business achieved revenue of 1.07 billion yuan, representing a year-on-year growth of over 37% [4]. - The company aims to adhere to its financial roots and continue to deepen its involvement in the Chengdu-Chongqing economic circle, enhancing its service model to support the real economy and cultivate new productive forces [4]. - The investment banking business is strategically focused, contributing to the overall growth of the company's operating performance [4].

Core Viewpoint - Southwest Securities predicts that the revenue of Insilico Medicine (03696) will reach $0.59 billion, $1.55 billion, and $2.02 billion for the years 2025-2027, with corresponding price-to-sales (PS) ratios of 78x, 30x, and 23x. The company's AI platform innovation capability has been validated, and long-term development is promising as more pipeline assets enter clinical stages and external licensing opportunities arise. The report initiates coverage with a recommendation for active attention [1]. Group 1: Core Competitiveness - The company's core competitiveness lies in its self-developed, globally leading end-to-end generative AI platform, Pharma.AI, which reduces the time from target discovery to clinical candidate confirmation from the industry average of 4.5 years to 12-18 months, validated through over 40 projects and 27 PCCs [2]. - The primary business model focuses on drug discovery and pipeline development, including external licensing, collaborative development, and independent development. Since 2026, the company has achieved three business development (BD) collaborations with upfront payments totaling $0.42 billion, and a total potential value of $10.74 billion. More BD collaborations are expected in 2026, potentially catalyzing stock price growth [1][3]. Group 2: Business Model - The company employs a dual-engine business model: 1) drug discovery and pipeline development through external licensing or collaborative development to obtain upfront payments, milestone payments, and sales shares; 2) software solutions generating subscription revenue from licensing the Pharma.AI platform. This model has been validated in the market, with nine external licensing agreements totaling over $4 billion in potential value and partnerships with 13 of the top 20 global pharmaceutical companies [3]. - The technology licensing generates cash flow and extensive validation data, while the success of internal pipelines further validates and enhances the AI platform's capabilities, creating a strong "data flywheel" effect [3]. Group 3: Pipeline and Product Potential - The company has nearly 20 clinical or IND application-stage assets generated from its platform, with the fastest pipeline, ISM001-055, being the world's first fully AI-discovered and designed candidate drug that has completed Phase IIa clinical trials for treating idiopathic pulmonary fibrosis (IPF). Recent clinical results show that patients receiving treatment exhibited dose-dependent improvements in lung function, with a significant difference of 118.7 milliliters compared to the placebo group [4]. - The IPF market presents substantial opportunities, and if ISM001-055 successfully reaches the market, it could become a disruptive therapy [4].

智通财经APP获悉，西南证券发布研报称，预计英矽智能(03696)2025-2027年对应营业收入分别为 0.59、1.55和2.02亿美元，对应PS为78倍、30倍和23倍。公司AI平台创新能力得到验证，长期发展值得 期待，随着更多管线资产进入临床和对外授权，公司有望迎来持续的价值兑现。首次覆盖，建议积极关 注。 西南证券主要观点如下： 公司核心竞争力在于其自研的全球领先的端到端生成式AI平台Pharma.AI 1）该平台将从靶点发现到临床前候选化合物确认的时间从行业平均的4.5年缩短至12-18个月，已通过 40+的项目，27个PCC得到充分验证；2）公司主要业务模式为药物发现及管线开发，包括对外授权、合 作开发和自主开发，26年至今公司已达成3项BD合作，首付款达0.42亿美元（含近期研发里程碑），总 金额达10.74亿美元。随着公司商业价值得到验证，26年有望达成更多BD合作，带来股价的直接催化； 3）自主开发的核心管线ISM001-055为全球AI制药唯一一款取得Ⅱ期临床数据的全AI研发药物，未来有 望成为颠覆性疗法，迎来持续的价值兑现。 全球领先的端到端AI制药平台，构筑核心技术壁垒 公司核心竞争 ...

Core Viewpoint - The recent resignation of the chairman of New Star Equipment, Li Weifeng, occurs amidst a period of significant performance recovery and stable stock price, raising questions about the timing and implications of this leadership change [1][2][6]. Group 1: Management Changes - On February 2, New Star Equipment announced the resignation of chairman Li Weifeng due to work adjustments, along with the resignation of independent director Liu Huaping [1][2]. - Li Weifeng will receive a compensation package not exceeding 1.2 million yuan, and his resignation constitutes a related party transaction but does not require shareholder approval [1][6]. - The board appointed Zhou Xina, the company secretary, to act as the chairman and legal representative until a new chairman is elected [1][6]. Group 2: Financial Performance - New Star Equipment forecasts a net profit attributable to shareholders of 32 million to 47.5 million yuan for 2025, representing a year-on-year growth of 69.32% to 151.34% [3][12]. - The company also expects to report a net profit of 9.5 million to 14 million yuan after excluding non-recurring gains and losses, a significant turnaround from a loss of 472,100 yuan in the previous year [3][12]. - The increase in profits is attributed to changes in non-recurring gains and the product delivery structure [3][12]. Group 3: Background of Li Weifeng - Li Weifeng, born in June 1985, has a strong financial background with an MBA from Tsinghua University and qualifications as a CPA and senior accountant [4][13]. - His career includes roles in auditing and investment banking before joining New Star Equipment in 2018, where he held various positions before becoming chairman in April 2022 [4][13]. - During his tenure, the company's main business remained stable, focusing on servo control technology for aerospace equipment, and the company has not faced any regulatory penalties or compliance issues [6][14]. Group 4: Market Reaction and Governance - The stock price of New Star Equipment remained stable, closing at 34.91 yuan with a slight increase of 0.06% on the day of the announcement, reflecting a market response to the management changes [3][12]. - The timing of the chairman's resignation, shortly after a positive earnings forecast, has drawn attention and may raise concerns about governance practices within the company [6][14]. - The company has emphasized that the resignation and compensation arrangements comply with legal regulations and will not adversely affect normal operations or minority shareholders' interests [7][14].

Group 1 - Core viewpoint: Companies are announcing significant financial updates, including profit changes, new product approvals, and share repurchase plans [1][2][3][4][5][6][15] Group 2 - Company: Chip导科技 reported a revenue of 394 million yuan for 2025, a year-on-year increase of 11.52%, but a net profit of 106 million yuan, down 4.91% [1] - Company: 亿帆医药's subsidiary received a drug registration certificate for Vitamin K1 injection, which is used for treating vitamin K deficiency [2] - Company: 勤上股份 announced the termination of its share repurchase plan to stabilize stock prices [3] - Company: 极米科技 plans to repurchase shares worth between 50 million and 100 million yuan for employee stock ownership plans [4] - Company: 凌云光 intends to change the purpose of repurchased shares to cancellation, reducing total share capital from 461 million to 457 million shares [5] - Company: 苏州科达's general manager resigned, and the chairman will take over the role to ensure management continuity [6] - Company: 银轮股份 identified 徐铮铮 as a co-actual controller, following a retrospective recognition [7] - Company: 西南证券 received approval to issue bonds up to 14 billion yuan [8] - Company: 上港集团 expects a 1.3% year-on-year increase in container throughput for January [10] - Company: 宁波富达 plans to distribute a cash dividend of 0.7 yuan per 10 shares, totaling 101 million yuan [11] - Company: 协和电子 is investing 5 million yuan in a venture capital fund to enhance its understanding of high-tech industries [12] - Company: 乐鑫科技's controlling shareholder proposed a share repurchase plan of 50 million to 100 million yuan [13] - Company: 奥瑞德's subsidiary plans to invest approximately 145 million yuan in computing power equipment [14] - Company: 上汽集团 reported a 23.94% year-on-year increase in vehicle sales for January [15] - Company: 道恩股份 plans to acquire a foreign company's plastic business for 15.737 million USD [16] - Company: 红相股份 intends to transfer 100% equity of 南通瀚蓝 for 120 million yuan [17] - Company: 长龄液压 announced a tender offer to acquire 12% of its shares at 35.82 yuan per share [19] - Company: 润都股份 faces uncertainty regarding the approval of its innovative drug [20] - Company: *ST东易's asset injection plans face significant uncertainty [21] - Company: 棒杰股份 is undergoing a restructuring process that could improve its financial structure [22] - Company: 绿联科技 has submitted an application for H-share listing in Hong Kong [23] - Company: ST泉为 is facing a creditor's application for restructuring [24] - Company: 海思科's shareholders plan to reduce their holdings by up to 0.89% [25] - Company: 钧崴电子's shareholder plans to reduce holdings by up to 3% [26]